WO2022136084A3 - Procédé et système pour produire des cellules mononucléées apoptotiques - Google Patents

Procédé et système pour produire des cellules mononucléées apoptotiques Download PDF

Info

Publication number
WO2022136084A3
WO2022136084A3 PCT/EP2021/086083 EP2021086083W WO2022136084A3 WO 2022136084 A3 WO2022136084 A3 WO 2022136084A3 EP 2021086083 W EP2021086083 W EP 2021086083W WO 2022136084 A3 WO2022136084 A3 WO 2022136084A3
Authority
WO
WIPO (PCT)
Prior art keywords
mononuclear cells
apoptotic mononuclear
producing
irradiation
producing apoptotic
Prior art date
Application number
PCT/EP2021/086083
Other languages
English (en)
Other versions
WO2022136084A2 (fr
Inventor
Sylvie LEFEBVRE
Chryslain Sumian
Original Assignee
Maco Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maco Pharma filed Critical Maco Pharma
Priority to CN202180086602.1A priority Critical patent/CN116916941A/zh
Priority to JP2023538027A priority patent/JP2023554529A/ja
Priority to AU2021406253A priority patent/AU2021406253A1/en
Priority to EP21844956.9A priority patent/EP4263442A2/fr
Publication of WO2022136084A2 publication Critical patent/WO2022136084A2/fr
Publication of WO2022136084A3 publication Critical patent/WO2022136084A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

Procédé et système pour produire des cellules mononucléées apoptotiques. L'invention concerne un procédé pour produire des cellules mononucléées apoptotiques contenues dans une fraction de sang périphérique d'un donneur, ledit procédé comprenant l'étape consistant à soumettre ladite fraction de sang à une irradiation ultraviolette ayant une longueur d'onde comprise entre 200 nm et 320 nm, ladite irradiation étant agencée pour induire une différence entre le taux d'apoptose des cellules irradiées et celui des cellules non irradiées supérieure à 15%, 48 heures après l'irradiation, de sorte à obtenir des cellules mononucléées apoptotiques capables de moduler la réponse immunitaire chez un patient.
PCT/EP2021/086083 2020-12-21 2021-12-16 Procédé et système pour produire des cellules mononucléées apoptotiques WO2022136084A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202180086602.1A CN116916941A (zh) 2020-12-21 2021-12-16 生成凋亡单核细胞的方法和系统
JP2023538027A JP2023554529A (ja) 2020-12-21 2021-12-16 アポトーシス単核球の製造方法および製造システム
AU2021406253A AU2021406253A1 (en) 2020-12-21 2021-12-16 Method and system for producing apoptotic mononuclear cells
EP21844956.9A EP4263442A2 (fr) 2020-12-21 2021-12-16 Procédé et système pour produire des cellules mononucléées apoptotiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR2013771 2020-12-21
FR2013771A FR3117872A1 (fr) 2020-12-21 2020-12-21 Procédé et système pour produire des cellules mononucléées apoptotiques

Publications (2)

Publication Number Publication Date
WO2022136084A2 WO2022136084A2 (fr) 2022-06-30
WO2022136084A3 true WO2022136084A3 (fr) 2022-10-20

Family

ID=75746754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/086083 WO2022136084A2 (fr) 2020-12-21 2021-12-16 Procédé et système pour produire des cellules mononucléées apoptotiques

Country Status (6)

Country Link
EP (1) EP4263442A2 (fr)
JP (1) JP2023554529A (fr)
CN (1) CN116916941A (fr)
AU (1) AU2021406253A1 (fr)
FR (1) FR3117872A1 (fr)
WO (1) WO2022136084A2 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551462A2 (fr) * 2002-10-11 2005-07-13 Baxter International Inc. Appareil, systemes et procedes utilisant la lumiere pour traiter un fluide biologique
US20070009377A1 (en) * 2005-07-06 2007-01-11 Navigant Biotechnologies, Inc. Methods for Reducing Pathogens in Biological Samples
US20100178200A1 (en) * 2007-06-22 2010-07-15 Maco Pharma S.A. Irradiation apparatus for inactivating pathogens and/or leukocytes in a biological fluid and process
US20100282980A1 (en) * 2009-05-11 2010-11-11 Caridianbct Biotechnologies, Llc Stable Calibration Means for Apparatus for Photo Reduction of Contaminants in Blood
US20120228517A1 (en) * 2005-12-23 2012-09-13 Harald Mohr Method for the inactivation of pathogens in donor blood, blood plasma or erythrocyte concentrates in flexible containers under agitation
WO2014087408A1 (fr) * 2012-12-06 2014-06-12 Enlivex Therapeutics Ltd Préparations de cellules apoptotiques thérapeutiques, méthode de production et utilisations associées
US20150283318A1 (en) * 2011-04-12 2015-10-08 Tianxin Wang Methods to detect and treat diseases
WO2016170541A1 (fr) * 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Préparations thérapeutiques à base de cellules apoptotiques sanguines regroupées et leurs utilisations
WO2020139495A1 (fr) * 2018-12-26 2020-07-02 Fenwal, Inc. Systèmes et procédés de photophérèse extracoprorelle à faible volume
US20200330628A1 (en) * 2019-04-16 2020-10-22 Fenwal, Inc. Systems and methods for photoactivation of a biological fluid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2525432A (en) 2014-04-24 2015-10-28 Univ Oslo Hf Modification of extracorporeal photopheresis technology with porphyrin precursors
GB201513278D0 (en) 2015-07-03 2015-09-09 Transimmune Ag And Yale University Device and method for obtaining immunostimulatory antigen-presenting cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551462A2 (fr) * 2002-10-11 2005-07-13 Baxter International Inc. Appareil, systemes et procedes utilisant la lumiere pour traiter un fluide biologique
US20070009377A1 (en) * 2005-07-06 2007-01-11 Navigant Biotechnologies, Inc. Methods for Reducing Pathogens in Biological Samples
US20120228517A1 (en) * 2005-12-23 2012-09-13 Harald Mohr Method for the inactivation of pathogens in donor blood, blood plasma or erythrocyte concentrates in flexible containers under agitation
US20100178200A1 (en) * 2007-06-22 2010-07-15 Maco Pharma S.A. Irradiation apparatus for inactivating pathogens and/or leukocytes in a biological fluid and process
US20100282980A1 (en) * 2009-05-11 2010-11-11 Caridianbct Biotechnologies, Llc Stable Calibration Means for Apparatus for Photo Reduction of Contaminants in Blood
US20150283318A1 (en) * 2011-04-12 2015-10-08 Tianxin Wang Methods to detect and treat diseases
WO2014087408A1 (fr) * 2012-12-06 2014-06-12 Enlivex Therapeutics Ltd Préparations de cellules apoptotiques thérapeutiques, méthode de production et utilisations associées
WO2016170541A1 (fr) * 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Préparations thérapeutiques à base de cellules apoptotiques sanguines regroupées et leurs utilisations
WO2020139495A1 (fr) * 2018-12-26 2020-07-02 Fenwal, Inc. Systèmes et procédés de photophérèse extracoprorelle à faible volume
US20200330628A1 (en) * 2019-04-16 2020-10-22 Fenwal, Inc. Systems and methods for photoactivation of a biological fluid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NARBUTT JOANNA ET AL: "The Effect of Repeated Exposures to Low-Dose UV Radiation on the Apoptosis of Peripheral Blood Mononuclear Cells", vol. 145, no. 2, 1 February 2009 (2009-02-01), US, XP055836359, ISSN: 0003-987X, Retrieved from the Internet <URL:http://dx.doi.org/10.1001/archdermatol.2008.574> DOI: 10.1001/archdermatol.2008.574 *
TUCHINDA CHANISADA ET AL: "Comparison of broadband UVB, narrowband UVB, broadband UVA and UVA1 on activation of apoptotic pathways in human peripheral blood mononuclear cells", PHOTODERMATOLOGY, PHOTOIMMUNOLOGY & PHOTOMEDICINE, WILEY-BLACKWELL PUBLISHING, INC, UNITED STATES, UNITED KINGDOM, vol. 23, no. 1, 1 February 2007 (2007-02-01), pages 2 - 9, XP002559839, ISSN: 0905-4383, DOI: 10.1111/J.1600-0781.2007.00260.X *

Also Published As

Publication number Publication date
CN116916941A (zh) 2023-10-20
FR3117872A1 (fr) 2022-06-24
AU2021406253A1 (en) 2023-07-06
JP2023554529A (ja) 2023-12-27
WO2022136084A2 (fr) 2022-06-30
EP4263442A2 (fr) 2023-10-25

Similar Documents

Publication Publication Date Title
JP2008503295A (ja) 電磁放射線の美容における使用
dos Santos Cardoso et al. Photobiomodulation for the aging brain
KR100888692B1 (ko) 숙성 마늘 및 숙성 마늘즙의 제조방법
CN109568231A (zh) 一种可祛红血丝的肤用组合物及其制备方法和应用
WO2022136084A3 (fr) Procédé et système pour produire des cellules mononucléées apoptotiques
Nadur-Andrade et al. Photobiostimulation reduces edema formation induced in mice by Lys-49 phospholipases A 2 isolated from Bothrops moojeni venom
Đurović et al. The effects of polarized light therapy in pressure ulcer healing
Buch et al. Photobiomodulation of the visual system and human health
MXPA04006828A (es) Metodo y proceso para producir piel con apariencia juvenil, con poros pequenos y tersa.
KR101611320B1 (ko) 홍삼 추출물 제조 방법
KR20180125757A (ko) 포포나무 유효성분의 추출 방법 및 그 추출물을 포함하는 조성물
Colić et al. The use of polarized light in aesthetic surgery
CN102178764B (zh) 一种能有效修复妊娠纹和疤痕的中药制剂
Aikawa et al. Cardiovascular calcification and bone mineralization
Munap et al. Wavelength and dose-dependent effects of photobiomodulation therapy on wound healing in rat model
Hamblin et al. Low-level light therapy aids traumatic brain injury
KR20140027790A (ko) 피부질환치료용 레이저빔 조사장치 및 조사방법
JP2023523514A (ja) 毛包メラノサイト幹細胞移植術による白斑治療方法
GB2336545A (en) Skin treatment
Hamblin Photobiomodulation and the brain–has the light dawned?
Alm et al. VNUS Closure radiofrequency ablation of varicose veins
Houreld Influence of 660 and 830 Nm Laser irradiation on genetic profile of extracellular matrix proteins in diabetic wounded human skin fibroblast cells
CN105695219A (zh) 一种蓝莓酒
RU2649505C1 (ru) Способ лечения себорейного дерматита с применением лазерной окситерапии
Jere et al. PHOTOBIOMODULATION AT 660 NM PROMOTES CELL PROLIFERATION THROUGH THE RELEASE OF BASIC FIBROBLAST GROWTH FACTOR AND ACTIVATION OF THE GSK3Β PATHWAY IN DIABETIC WOUNDED FIBROBLAST CELLS IN VITRO

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21844956

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202180086602.1

Country of ref document: CN

Ref document number: 2023538027

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2021406253

Country of ref document: AU

Date of ref document: 20211216

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2021844956

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021844956

Country of ref document: EP

Effective date: 20230721